AU2017298262B2 - Radioligands for imaging the IDO1 enzyme - Google Patents

Radioligands for imaging the IDO1 enzyme Download PDF

Info

Publication number
AU2017298262B2
AU2017298262B2 AU2017298262A AU2017298262A AU2017298262B2 AU 2017298262 B2 AU2017298262 B2 AU 2017298262B2 AU 2017298262 A AU2017298262 A AU 2017298262A AU 2017298262 A AU2017298262 A AU 2017298262A AU 2017298262 B2 AU2017298262 B2 AU 2017298262B2
Authority
AU
Australia
Prior art keywords
ido1
radiolabeled compound
tissues
imaging
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017298262A
Other languages
English (en)
Other versions
AU2017298262A1 (en
Inventor
Alban J. ALLENTOFF
James Aaron Balog
Richard Charles BURRELL
Erin Lee COLE
David J. Donnelly
Audris Huang
Mette SKINBJERG
Wesley A. TURLEY
Michael Arthur WALLACE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AU2017298262A1 publication Critical patent/AU2017298262A1/en
Application granted granted Critical
Publication of AU2017298262B2 publication Critical patent/AU2017298262B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Quinoline Compounds (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2017298262A 2016-07-19 2017-07-18 Radioligands for imaging the IDO1 enzyme Active AU2017298262B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662364020P 2016-07-19 2016-07-19
US62/364,020 2016-07-19
PCT/US2017/042510 WO2018017529A1 (en) 2016-07-19 2017-07-18 Radioligands for imaging the ido1 enzyme

Publications (2)

Publication Number Publication Date
AU2017298262A1 AU2017298262A1 (en) 2019-03-07
AU2017298262B2 true AU2017298262B2 (en) 2024-07-18

Family

ID=59416832

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017298262A Active AU2017298262B2 (en) 2016-07-19 2017-07-18 Radioligands for imaging the IDO1 enzyme

Country Status (13)

Country Link
US (2) US20190282714A1 (enExample)
EP (1) EP3487516A1 (enExample)
JP (1) JP6987840B2 (enExample)
KR (1) KR102513886B1 (enExample)
CN (1) CN109475594A (enExample)
AU (1) AU2017298262B2 (enExample)
BR (1) BR112019000499A2 (enExample)
CA (1) CA3031079A1 (enExample)
EA (1) EA039877B1 (enExample)
IL (1) IL264187B (enExample)
MX (1) MX2019000508A (enExample)
SG (1) SG11201900336YA (enExample)
WO (1) WO2018017529A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019528300A (ja) * 2016-08-26 2019-10-10 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ インドールアミン２，３−ジオキシゲナーゼの阻害剤およびその使用方法
WO2019006292A1 (en) * 2017-06-30 2019-01-03 Bristol-Myers Squibb Company SUBSTITUTED QUINOLINYCYCLOHEXYLPROPANAMIDE COMPOUNDS AND IMPROVED PROCESSES FOR THE PREPARATION THEREOF
KR20200088410A (ko) * 2017-11-21 2020-07-22 광동 오포 모바일 텔레커뮤니케이션즈 코포레이션 리미티드 정보 전송 방법, 네트워크 디바이스 및 단말기 디바이스
EP3720843A1 (en) * 2017-12-05 2020-10-14 GlaxoSmithKline Intellectual Property Development Limited Modulators of indoleamine 2,3-dioxygenase
CN110357813A (zh) * 2018-04-09 2019-10-22 信达生物制药(苏州)有限公司 一种新型吲哚胺2,3-双加氧酶抑制剂及其制备方法和用途
AR120935A1 (es) * 2020-01-02 2022-03-30 Hutchison Medipharma Ltd Derivados de amida y usos de los mismos

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101182359A (zh) * 2007-11-09 2008-05-21 中山大学 人吲哚胺2,3-双加氧酶多克隆抗体及其制备方法和应用
WO2011109262A2 (en) * 2010-03-01 2011-09-09 Tau Therapeutics Llc Cancer diagnosis and imaging
WO2016040458A2 (en) * 2014-09-09 2016-03-17 H. Lee Moffitt Cancer Center And Research Institute, Inc. Pet probes of radiofluorinated carboximidamides for ido-targeted imaging
UY36390A (es) * 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen

Also Published As

Publication number Publication date
BR112019000499A2 (pt) 2019-04-24
US20190282714A1 (en) 2019-09-19
US20220305144A1 (en) 2022-09-29
JP2019527225A (ja) 2019-09-26
IL264187A (en) 2019-02-28
CA3031079A1 (en) 2018-01-25
KR102513886B1 (ko) 2023-03-27
WO2018017529A1 (en) 2018-01-25
KR20190030727A (ko) 2019-03-22
AU2017298262A1 (en) 2019-03-07
EP3487516A1 (en) 2019-05-29
CN109475594A (zh) 2019-03-15
EA201990198A1 (ru) 2019-06-28
JP6987840B2 (ja) 2022-01-05
SG11201900336YA (en) 2019-02-27
IL264187B (en) 2021-06-30
MX2019000508A (es) 2019-03-28
EA039877B1 (ru) 2022-03-23

Similar Documents

Publication Publication Date Title
US20220305144A1 (en) Radioligands for imaging the id01 enzyme
US20250057995A1 (en) Radioligands for imaging the lpa1 receptor
CN106977429B (zh) 用于合成和使用造影剂的组合物、方法和系统
TWI589302B (zh) 用於合成造影劑及其中間體之方法及裝置
CN101448834A (zh) 2-芳基吡唑并[1,5-α]嘧啶-3-基乙酰胺衍生物作为转运蛋白(18kDa)配体
EP3062827A1 (en) Radioligands for imaging the lpa-1 receptor
KR20080105766A (ko) 베타아밀로이드 침착의 영상화를 위한 헤테로사이클릭 인덴계열의 유도체 및 그의 방사성 동위원소 표지화합물
WO2013173746A2 (en) Use of fluorinated derivatives of 4-aminopyridine in therapeutics and medical imaging
US20250340562A1 (en) Chromane imaging ligands
KR101519006B1 (ko) 신규한 벤즈아마이드 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 피부암 진단용 약학적 조성물
US20250222145A1 (en) Tracer composition for radioactive pet diagnosis, intermediate thereof, and production method thereof
WO2025188917A1 (en) Construction and use of reagents for conjugation to bioligands for imaging and radiopharmaceutical applications
JP2024534191A (ja) ブルトン型チロシンキナーゼのｐｅｔ画像化に有用な化合物
HK1241356A1 (en) Compositions, methods and systems for the synthesis and use of imaging agents
L’Estrade et al. Development in ankylosing spondylitis has been suspended after the drug failed to show clinical benefit over methotrexate in a phase II trial. Menu
HK1182933A (en) Compositions, methods and systems for the synthesis and use of imaging agents

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)